St. Jude Medical
This article was originally published in The Gray Sheet
Executive Summary
Firm receives IDE approval from FDA to begin its Post AV Node Ablation Evaluation (PAVE) clinical trial for patients with chronic atrial fibrillation receiving an 'ablate and pace' procedure, St. Jude announces Aug. 22. The 600-patient, 65-center study will compare the effects of left ventricular or biventricular pacing with right ventricular pacing, which is the current standard of care. The study, which will use St. Jude's Frontier stimulation device and Aescula left heart lead, will randomize patients to one of three arms. Patients in the left ventricular arm will also receive a right ventricular lead to provide backup right ventricular pacing. Endpoints include the six-minute walk test and quality of life assessment
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.